Compassionate use

What it is

Compassionate use is access to an unapproved medicine outside a clinical trial for a patient with a serious disease when no satisfactory options exist. The key point is that it is not the same as joining a clinical trial: the main purpose is treatment for a patient with urgent need, not research, although safety and outcome data may still be collected.

Different regulators use different terms. In the United States, the FDA usually calls this expanded access. In the European Union, regulators commonly use compassionate use for programmes that make an unauthorised medicine available to groups of patients, while named-patient routes may be used for individuals. In practice, patients and families often use the terms compassionate use, compassionate access, and expanded access interchangeably.

Compassionate use is usually considered when all of the following apply:

1. The illness is serious or immediately life-threatening.
2. Standard approved treatments are unavailable, unsuitable, or have stopped working.
3. The patient cannot enter a relevant clinical trial, often because of location, eligibility criteria, or trial closure.
4. The treating doctor and the manufacturer are willing to request and supply the medicine.
5. The expected potential benefit is judged to justify the known and unknown risks.

For cancer care, this may arise when a patient has advanced disease, has exhausted standard lines of therapy, and there is a promising investigational drug that is still under study or awaiting approval.

Term	Usual meaning
Compassionate use	Access to an unapproved medicine outside a trial for patients with serious disease
Expanded access	Common US regulatory term for compassionate use
Named-patient access	Supply for an individual patient, often under national rules
Clinical trial	Research study designed to test safety and effectiveness

In India, access pathways can be more complex because availability depends on the product, sponsor, hospital, ethics oversight, and Central Drugs Standard Control Organisation, or CDSCO, requirements. Patients should expect that compassionate use is exceptional, case-specific, and often administratively demanding.

How it works

Compassionate use usually starts with the treating specialist, not the patient alone. The doctor identifies a medicine that may be relevant, reviews the patient's condition and prior treatments, and checks whether a suitable clinical trial is available. If trial participation is possible, that is often preferred because trials have structured monitoring and can help answer scientific questions.

If a trial is not feasible, the doctor may approach the manufacturer or sponsor to ask whether the drug can be supplied outside the trial. Companies are not always able or willing to provide access. Reasons include limited drug supply, concern about safety, lack of a formal access programme, cost, logistics, or fear that uncontrolled use could complicate development.

If the company agrees in principle, regulatory and ethics steps usually follow. These may include:

1. A clinical justification from the treating doctor.
2. Informed consent explaining that the medicine is investigational and may not help.
3. Approval or notification under the relevant national regulatory pathway.
4. Safety monitoring and adverse-event reporting.

Compassionate use can occur in two broad forms:

• Individual-patient access: one patient receives the medicine.
• Programmatic access: a group of patients with similar conditions may receive it under a defined protocol.

Although the primary goal is treatment, information from compassionate-use patients can sometimes contribute to real-world evidence. Published reviews note that such data may help describe safety, dosing patterns, and outcomes in patients who are often sicker or less selected than trial participants. Still, these data are usually less reliable than randomised trial data because there is no control group and many sources of bias.

Evidence and uses

Compassionate use is not proof that a medicine works. It is a pathway for access when evidence is still incomplete. Some drugs later become standard treatments; others do not, because later studies show limited benefit, unexpected harms, or both.

Potential reasons to consider compassionate use include:

• advanced cancer with no satisfactory approved options
• rare cancers or molecular subtypes with few trials
• inability to meet trial eligibility criteria
• urgent clinical deterioration while approval is pending

What evidence supports use depends on the specific drug. Sometimes there are only early phase trial results. In other cases, a drug may already be approved in another country or for another disease, but not yet approved for the patient's exact indication.

A practical way to think about the evidence is:

Evidence level	What it may mean for compassionate use
Laboratory or animal data only	Very uncertain benefit in humans
Early phase human studies	Some signal of activity, but safety and effectiveness still unclear
Later phase or published trial data	Stronger rationale, but not the same as local approval
Approval in another country	Suggests more evidence exists, but access and indication still matter

For oncology, compassionate use may be discussed for targeted therapies, immunotherapies, cell therapies, or rare-disease medicines. However, access is often uneven. Cost, import rules, hospital capability, and manufacturer policy can all limit availability. In India, this may be especially relevant for high-cost biologics and precision oncology drugs that are not yet routinely available.

When to see a clinician

Ask your oncologist about compassionate use if you have a serious illness and:

1. Standard treatments have been exhausted or are not suitable.
2. You were told there is a promising drug but no open trial you can join.
3. Your cancer has a rare mutation or subtype with limited approved options.
4. You want to understand all realistic treatment pathways, including palliative care and best supportive care.

A useful discussion with the treating team should cover:

• the exact drug being considered
• what evidence exists so far
• known side effects and unknown risks
• whether a clinical trial is available and preferable
• who would pay for the drug, tests, admission, and monitoring
• how quickly access could realistically happen

Patients and families should be cautious about online claims that compassionate use is a guaranteed route to breakthrough treatment. It is not guaranteed, and delays can be substantial.

Limitations and open questions

Compassionate use raises ethical and practical questions. It may offer hope, but it can also expose very unwell patients to drugs with uncertain benefit and incomplete safety data. Access is often unequal because it depends on geography, specialist networks, manufacturer decisions, and ability to manage costs.

Evidence from compassionate-use programmes is useful but limited. Published analyses note that real-world data from expanded-access patients can sometimes inform drug development, especially for rare diseases, but these data are vulnerable to selection bias, missing data, and inconsistent follow-up. They should not be treated as equivalent to randomised controlled trial evidence.

Another open question is fairness. Regulators and ethicists continue to debate how to balance rapid access for patients in need with the need to protect patients and preserve enrollment in clinical trials. If too many eligible patients bypass trials, it can become harder to generate the evidence needed for full approval.

For patients in India, the most important practical point is that compassionate use is a case-by-case access pathway, not a standard entitlement. The best next step is usually to speak with the treating specialist at a centre experienced in clinical trials, regulatory applications, and advanced cancer care.